Who owns EUPRAXIA PHARMACEUTICALS INC.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of EPRX from SEC Form 13F filings across 70 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 70 institutions disclosed 30.5M shares of EUPRAXIA PHARMACEUTICALS INC. worth $277.6M — about 76.3% of shares outstanding; the largest disclosed holder is Beutel, Goodman & Co Ltd.. Source: SEC Form 13F filings, parsed by EvidInvest.
70
13F holders
$277.6M
value, 2026 filers
76.3%
of shares outstanding (30.5M sh)
13
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of EPRX's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | Beutel, Goodman & Co Ltd. | 3.5M | $32.3M | 0.3% | 8.8% | -2.7% |
| 2 | Janus Henderson Group Ltd.NEW | 2.7M | $25.0M | 0.0% | 6.8% | new |
| 3 | Bellevue Group AGNEW | 2.6M | $23.6M | 0.5% | 6.5% | new |
| 4 | Affinity Asset Advisors, LLC | 1.7M | $15.6M | 0.6% | 4.3% | +4.0% |
| 5 | SCOTIA CAPITAL INC. | 1.4M | $12.9M | 0.0% | 3.6% | +6.1% |
| 6 | Balyasny Asset Management L.P. | 1.4M | $12.7M | 0.0% | 3.5% | +3.1% |
| 7 | Vivo Capital, LLC | 1.4M | $12.3M | 1.4% | 3.4% | 0.0% |
| 8 | GREAT POINT PARTNERS LLC | 1.2M | $10.9M | 2.6% | 3% | 0.0% |
| 9 | Caligan Partners LPNEW | 1.2M | $10.6M | 0.6% | 2.9% | new |
| 10 | PFM Health Sciences, LP | 1.1M | $10.3M | 1.0% | 2.8% | -6.8% |
| 11 | CITADEL ADVISORS LLC | 978,875 | $8.9M | 0.0% | 2.4% | +95.0% |
| 12 | Rubric Capital Management LP | 867,424 | $7.9M | 0.1% | 2.2% | 0.0% |
| 13 | Ikarian Capital, LLC | 809,741 | $7.4M | 0.7% | 2% | 0.0% |
| 14 | Woodline Partners LP | 746,864 | $6.8M | 0.0% | 1.9% | 0.0% |
| 15 | AMERIPRISE FINANCIAL INC | 709,691 | $6.5M | 0.0% | 1.8% | -0.2% |
| 16 | Alyeska Investment Group, L.P. | 629,992 | $5.7M | 0.0% | 1.6% | +68.0% |
| 17 | Seven Fleet Capital Management LP | 572,267 | $5.2M | 1.0% | 1.4% | -6.3% |
| 18 | SummitTX Capital, L.P.NEW | 522,753 | $4.8M | 0.1% | 1.3% | new |
| 19 | Redmile Group, LLC | 519,881 | $4.7M | 0.3% | 1.3% | -15.0% |
| 20 | TWO SIGMA INVESTMENTS, LP | 469,068 | $4.3M | 0.0% | 1.2% | +112.2% |
| 21 | DAFNA Capital Management LLC | 404,567 | $3.7M | 0.8% | 1% | +79.3% |
| 22 | BOOTHBAY FUND MANAGEMENT, LLC | 369,120 | $3.4M | 0.1% | 0.9% | +73.6% |
| 23 | Velan Capital Investment Management LP | 352,000 | $3.2M | 3.1% | 0.9% | 0.0% |
| 24 | PICTON MAHONEY ASSET MANAGEMENT | 344,001 | $3.1M | 0.0% | 0.9% | -4.7% |
| 25 | Aisling Capital Management LP | 325,000 | $3.0M | 1.0% | 0.8% | 0.0% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.